Haplotypic Analysis of MDR1 and Risk for Cervical Cancer in Northeastern Thailand

Sophida Phuthong1, Wannapa Settheetham-Ishida1*, Sitakan Natphopsuk2, Dariwan Settheetham3, Takafumi Ishida4

Abstract

Objective: The aim of this study was to investigate the association between genotype and haplotype of MDR1 (C1236T, G2677T/A and C3435T) and the risk for cervical cancer in Northeastern Thai women. Methods: An age-matched case-control study involving squamous cell cervical cancer (SCCA) patients (n=204) and healthy controls (n=204) was enrolled for MDR1 genotyping by real-time PCR method. Results: The genotype distribution of MDR1 in both patients and controls was not significantly different (p>0.05). The haplotype analysis showed that T-T-T was the most common haplotype in this population. Significantly increased risk of cervical cancer was observed in carriers of T-T-C and C-G-T haplotypes with ORs of 1.86 (95%CI=1.02-3.39, p=0.0416) and 2.00 (95%CI=1.18-3.40, p=0.0140), respectively. Analysis of 2677-3435 haplotype showed increased risk for cervical cancer in G-T (OR=1.55; 95%CI=1.12-2.13, p=0.0432) and T-C (OR=1.91; 95%CI=1.05-3.47, p=0.0325). Conclusion: The results provide evidence that haplotype of MDR1 may be an important risk factor for cervical cancer development in Northeastern Thai women.

Keywords: MDR1- cervical cancer- haplotype- Northeastern Thailand

Introduction

The multidrug resistance 1 (MDR1) gene located on chromosomal region 7q21 encodes P-glycoprotein (P-gp). P-gp is a membrane transporter of an ATP-dependent efflux pump which contributes to protecting the body from environmental toxins and carcinogenic compounds. It is widely expressed on the membrane of normal tissues, such as breast, colon, gastric and cervical tissues (Marzolini et al., 2004; Nicol et al., 2014; Riou et al., 1990).

The MDR1 is a highly polymorphic gene with at least 50 single nucleotide polymorphisms (SNPs) (Fung and Gottesman, 2009). The most common three SNPs are C1236T, G2677T/A and C3435T in the exon 12, 21 and 26, respectively (Kimchi-Sarfaty et al., 2007(a); Panczyk et al., 2009). C1236T and C3435T are silent mutations that do not change the encoded amino acid, whereas non-synonymous G2677T/A results in an amino acid substitution from alanine to serine or threonine. Polymorphisms of the MDR1 may lead to inter-individual variation of P-gp expression and function, and may influence inter-individual carcinogenic susceptibility (Wang et al., 2005).

Among the identified MDR1 SNPs, C3435T was the first SNP correlated with expression levels and function of P-gp (Hitzl et al., 2001; Hoffmeyer et al., 2000). Several studies have reported that genetic variations of the MDR1 alter the risk of cancer development which is more apparent in haplotype analysis with other two, C1236T and G2677T/A, SNPs (Abuhaliema et al., 2016; Panczyk et al., 2009; Potocnik et al., 2008; Wu et al., 2012). Carriers of the T allele of C3435T were mostly found with the increased risk for cancer in colon, renal and breast (Kurzawski et al., 2005; Siegsmund et al., 2002; Turgut et al., 2007), while some studies reported that carriers of the C allele had an increased risk of colorectal cancer and breast cancer (Abuhaliema et al., 2016; Yue et al., 2013). However, no significant relationships between the polymorphism and increased colorectal cancer (Petrova et al., 2008), breast cancer (Rubis et al., 2012) and gastric cancer (Zebrowska et al., 2014) have also reported.

Since the C3435T polymorphism is in linkage disequilibrium with C1236T and G2677T/A polymorphisms (Kimchi-Sarfaty et al., 2007(b)), haplotype analyses for the three polymorphisms may provide more useful information than simple genotypic analyses. Therefore, our study was designed to determine whether the MDR1 polymorphisms and their haplotype are associated with the risk for developing cervical cancer among Northeastern Thai women.

1Department of Physiology, HPV and EBV and Carcinogenesis Research Group, Faculty of Medicine, 2Department of Environmental Health, Faculty of Public Health, Khon Kaen University, Khon Kaen, 3Chulabhorn International College of Medicine, Thammasat University, Pathum Thani, Thailand, 4Department of Biological Sciences, Graduate School of Science, The University of Tokyo, Tokyo, Japan. *For Correspondence: wannapa@kku.ac.th
Materials and Methods

Study population
This case-control study was conducted in Khon Kaen Hospital and Srinagarind Hospital, Khon Kaen Province, Northeastern Thailand. Participants were 204 women with pathologically diagnosed squamous cell carcinoma of the cervix (SCCA) and 204 healthy women without cervical cancer and/or pre-invasive lesion of the cervix confirmed by cytological and histological examination. The controls were matched to the cases on age within 5 year interval. The study protocol was approved by the Ethics Committee of Khon Kaen University (HE 561382) and a signed informed consent was obtained from each participant.

Detection of MDR1 polymorphism
Genomic DNA was extracted from buffy coat using GF-1 Blood DNA Extraction Kits (Vivantis, USA). The real-time polymerase chain reaction with TaqMan® probe (Applied Biosystems, USA) was used for the detection of MDR1 polymorphisms. Taqman® probe was designed for specific SNP, VIC fluorescence dye’s probe was used for wild type allele (C allele) whereas FAM fluorescence dye’s probe was used for mutant type allele (T allele) of C1236T and C3435T. For G2677T/A SNP which provided two types of variant allele (T and A alleles) performed in two assays, one for the detection of G and A alleles and another for the detection of G and T alleles, VIC probe was specific with the G allele and FAM probe was specific with the A allele or T allele. The reactions were set under the following conditions: for C1236T (rs1128503) and C3435T (rs1045642) SNPs, holding stage at 95 °C for 10 minutes, follow by 40 cycles each of denaturation at 95 °C for 15 seconds, annealing and extension at 60 °C for 60 seconds. For G2677T/A (rs2032582) SNP, holding stage at 95 °C for 10 minutes, follow by 40 cycles each of denaturation at 95 °C for 15 seconds, annealing and extension at 60 °C for 60 seconds.

Statistical analyses
Statistical analyses were performed using STATA software. Deviation from Hardy-Weinberg equilibrium (HWE) for the genotype of each SNP was tested by Pearson’s chi-square. The haplotypes were inferred using PHASE algorithm version 2.1.1. Association between genotype or haplotype and cervical cancer risk was tested by calculating the odd ratios (OR) with 95% confidence intervals (CI) by logistic regression analyses.

Results
The genotype distribution and allele frequency of the MDR1 polymorphisms (C1236T, G2677T/A and C3435T) are summarized in Table 1. The genotype distribution for each locus among the cases and controls was in agreement with Hardy-Weinberg equilibrium (p > 0.05). The genotype distribution of C1236T, G2677T/A and C3435T in both patients and controls were not different and no association was found between these genotype and cervical cancer risk. For the allele distribution, only the C3435T polymorphism showed significantly different distribution between cases and controls (p=0.042), which indicated that the presence of T allele gave a higher risk for cervical cancer.

Table 2 presents the distribution of haplotype for the MDR1 polymorphisms (1236-2677-3435) and risk for cervical cancer.

Table 1. Genotype Distribution and Allele Frequency of The MDR1 in Cervical Cancer

| Position | Exon | Amino acid change | Genotype/ Allele | Number/Frequency |
|----------|------|-------------------|------------------|-----------------|
| CC       | 3435 | T-T-T             | CT               | 96              |
|         |      |                   | TT               | 84              |
|         |      |                   | C               | 0.35            |
|         |      |                   | T               | 0.65            |
| GG      | 2677 | Ala893Ser/Thr     | GT               | 148             |
|         |      |                   | GA               | 10              |
|         |      |                   | TT               | 47              |
|         |      |                   | TA               | 7               |
|         |      |                   | AA               | 1               |
|         |      |                   | G               | 0.50            |
|         |      |                   | T               | 0.45            |
|         |      |                   | A               | 0.05            |
| CC      | 1236 | Gly412Gly         | CT               | 24              |
|         |      |                   | TT               | 23              |
|         |      |                   | C               | 0.71            |
|         |      |                   | T               | 0.71            |
| CC      | 3435 | T-T-T             | CT               | 96              |
|         |      |                   | TT               | 84              |
|         |      |                   | C               | 0.35            |
|         |      |                   | T               | 0.65            |
| GC      | 2677 | Ala893Ser/Thr     | GT               | 148             |
|         |      |                   | GA               | 10              |
|         |      |                   | TT               | 47              |
|         |      |                   | TA               | 7               |
|         |      |                   | AA               | 1               |
|         |      |                   | G               | 0.50            |
|         |      |                   | T               | 0.45            |
|         |      |                   | A               | 0.05            |
| CT      | 1236 | Ile1145Ile        | CT               | 24              |
|         |      |                   | TT               | 23              |
|         |      |                   | C               | 0.71            |
|         |      |                   | T               | 0.71            |
| CT      | 3435 | Ile1145Ile        | CT               | 24              |
|         |      |                   | TT               | 23              |
|         |      |                   | C               | 0.71            |
|         |      |                   | T               | 0.71            |

* a, no deviation from Hardy–Weinberg equilibrium; b, no deviation from Hardy–Weinberg equilibrium; c, allele distribution of Ile1145Ile (C/T) was different between case and control (p=0.042)

Table 2. Association between MDR1 Haplotypes (1236-2677-3435) and Risk for Cervical Cancer

| MDR1 | Case | Control |
|------|------|---------|
| 1236- | n (%) | n (%) |
| 2677- | [95%CI, p] | [95%CI, p] |
| 3435- | T-T-T as standard | in haplotype pair |
| T-T-T | 148 (36.27) | 145 (35.54) |
| T-T-C | 36 (8.82) | 19 (4.66) |
| C-G-C | 73 (17.89) | 90 (22.06) |
| C-G-T | 51 (12.50) | 25 (6.13) |
| C-A-C | 9 (2.21) | 17 (4.17) |
| C-A-T | 10 (2.45) | 6 (1.47) |
| T-G-C | 59 (14.46) | 81 (19.85) |
| T-G-T | 21 (5.15) | 20 (4.90) |
| C-T-C | 1 (0.26) | 0 (0.00) |
| C-T-T | 0 (0.00) | 5 (0.12) |

*p<0.05; b, drop because confidence levels not possible with zero count cells
three loci of \textit{MDR1} (1236-2677-3435). The haplotype T-T-T was most frequently observed both in cases and controls. T-T-C and C-G-T haplotypes significantly increased the risk for cervical cancer compared to T-T-T with OR=1.86 (95% CI=1.02-3.39, \(p=0.042\)) and OR=2.00 (95% CI=1.18-3.40, \(p=0.014\)), respectively. Furthermore, carriers of C-G-G had 2.5 times higher risk of cervical cancer compared to the Caucasian and African common C-G-C haplotype (95% CI=1.42-4.45, \(p=0.021\)).

**Discussion**

The \textit{MDR1} polymorphisms have been intensively studied so far, mostly focusing on the role of C3435T (Fung and Gottesman, 2009; Wang et al., 2005). C3435T correlated with other SNPs i.e. G2677T/A and C1236T that have been shown to be a part of common haplotypes, is the main determinant of functional differences in P-gp (Kimchi-Sarfaty et al., 2007b; Panczyk et al., 2009). Analysis of \textit{MDR1} haplotype likely provide a better understanding of \textit{MDR1} polymorphism on cancer risk rather than their allelic frequency distribution for each individual SNP.

In our result, the genotype distributions for the three \textit{MDR1} SNPs in the controls were in Hardy-Weinberg equilibrium which confirmed they represented the given population. Among healthy Thais, the commonest allele for each locus was T (C1236T), G (G2677T/A) and C (C3435T) as in other Asian populations but was different from that in European-Americans and Caucasians (Ameyaw et al., 2001; Cascorbi et al., 2001, Kim et al., 2001; Komoto et al., 2006; Li et al., 2007; Tang et al., 2002; Wang et al., 2015), showing inter-ethnic differences. As for C3435T, risk for several cancers, such as breast, endometrial and colorectal have been documented (Cizmarikova et al., 2010; Mrozikiewicz et al., 2007; Khedri et al., 2011; Wu et al., 2012), whereas in this study, T allele itself showing significantly higher risk for cervical cancer was observed nevertheless genotype was not involved in.

Because of the linkage disequilibrium, the haplotype frequencies were not of the representative of allelic frequencies; T-T-T haplotype was the most common haplotype in our population. It is documented that this haplotype is a predominant haplotype among Asian populations (Fung and Gottesman, 2009; Xu et al., 2008), whereas C-G-C haplotype is a predominant haplotype in Caucasian and African populations (Fung and Gottesman, 2009; Gumus-Akay et al., 2010; Jeannesson et al., 2007); here observed is inter-ethnic difference, too.

Participation of \textit{MDR1} polymorphisms in the alteration of risk for cervical cancer might be due to the change of P-gp function which is likely influenced by the 2677-3435 haplotype (Kwon et al., 2009, Ni et al., 2015, Pang et al., 2014). A study of 2677-3435 haplotype demonstrated that G-T haplotype contributed to diffuse large B cell lymphoma development (Ni et al., 2015) which was in agreement with our findings; significant increased risk for cervical cancer was observed in carriers of G-T haplotype (C-G-T and T-G-T) with OR 1.546 (95% CI=1.12-2.13, \(p=0.043\)) compared to T-T haplotype. A significant increased risk for cervical cancer was also observed in T-C haplotype (OR=1.908 95% CI=1.05-3.47, \(p=0.033\)); however, A-T haplotype did not show an increased risk. It is suggested that the presence of T allele in these two loci may alter susceptibility to cervical cancer. The presence of variant alleles has been associated with lower mRNA expression and less production of P-gp which results in carcinogen accumulation (Lamba et al., 2006, Johne et al., 2002). In addition, a possible explanation for different P-gp function observed within the \textit{MDR1} haplotype may result from the interaction of C1236T, G2677T/A and C3435T leading to the presence of rare codon. Alteration of codon influences the co-translational folding time and insertion of P-gp into the membrane, thereby change of P-gp structure and substrate specificity (Kimchi-Sarfaty et al., 2007b).

In conclusion, our finding demonstrates the association between haplotype of \textit{MDR1} and cervical cancer risk in Northeastern Thai women. The haplotype testing to identify genetic susceptibility may provide more information for the cancer prevention.

**Acknowledgements**

The authors thank all the staff and the patients who took part in this study. This study was partly supported by (a) a Research Fund for Supporting Lecturer to Admit High Potential Student to Study and Research on Expert Program Year 2015 (581H218), Graduate School, Khon Kaen University, (b) an Invitation Research Grant from Faculty of Medicine (IN60214), Khon Kaen University, (c) a Research Fund from Khon Kaen University, and (d) JSPS Core University Program.

**References**

Abuhamiea AM, Yousef AM, El-Madany NN, et al (2016). Influence of genotype and haplotype of \textit{MDR1} (C3435T, G2677T/A, C1236T) on the incidence of breast cancer-a case-control study in Jordan. \textit{Asian Pac J Cancer Prev}, \textbf{17}, 261-6.

Andersen V, Vogel U, Godiksen S, et al (2013). Low \textit{ABCB1} gene expression is an early event in colorectal carcinogenesis. \textit{PloS One}, \textbf{8}, e72119.

Brambila-Tapia AJ (2013). \textit{ABCB1} (\textit{MDR1}) polymorphisms: functional effects and clinical implications. \textit{Rev Invest Clin}, \textbf{65}, 445-54.

Cascorbi I, Gerloff T, Johne A, et al (2001). Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter \textit{MDR1} gene in white subjects. \textit{Clin Pharmacol Ther}, \textbf{69}, 169-74.

Cizmarikova M, Wagnerova M, Schonova L, et al (2010). \textit{MDR1} (C3435T) polymorphism: relation to the risk of breast cancer and therapeutic outcome. \textit{Pharmacogenomics J}, \textbf{10}, 62-9.

Fung KL, Gottesman MM (2009). A synonymous polymorphism in a common \textit{MDR1} (\textit{ABCB1}) haplotype shapes protein function. \textit{Biochim Biophys Acta}, \textbf{1794}, 860-71.

Gaikovitch E, Mrozikiewicz P, Wagner F, Roots I (2004). Association of C3435T and G2677T/A polymorphisms of multidrug resistance (\textit{MDR1}) gene with colorectal cancer risk. \textit{Clin Pharmacol Ther}, \textbf{75}, P17.

Gumus-Akay G, Rustemoglu A, Karadag A, Sunguroglu A

\textbf{DOI:10.22034/APJCP.2017.18.7.1815}
Sophida Phuthong et al

(2010). Haplotype-based analysis of MDR1/ABCB1 gene polymorphisms in a Turkish population. DNA Cell Biol, 29, 83-90.

Hitzi M, Drescher S, van der Kuip H, et al (2001). The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56(+) natural killer cells. Pharmacogenetics, 11, 293-8.

Hoffmeyer S, Burk O, von Richter O, et al (2000). Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A, 97, 3473-8.

Jeannesson E, Albertini L, Siest G, et al (2007). Determination of ABCB1 polymorphisms and haplotypes frequencies in a French population. Fundam Clin Pharmacol, 21, 411-8.

Johne A, Kopke K, Gerloff T, et al (2002). Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther, 72, 584-9.

Khedri A, Nejat-Shokouhi A, Salek R, et al (2011). Association of the colorectal cancer and MDR1 gene polymorphism in an Iranian population. Mol Biol Rep, 38, 2939-43.

Kim RB, Leake BF, Choo EF, et al (2001). Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther, 70, 189-99.

Kimchi-Sarfaty C, Marple AH, Shinar S, et al (2007b). A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science, 315, 525-8.

Kimchi-Sarfaty C, Oh JM, Kim IW, et al (2007b). A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science, 315, 525-8.

Kimoto C, Nakamura T, Sakaeda T, et al (2006). Ethnicity-related polymorphisms and haplotypes in the human ABCB1 gene. Pharmacogenomics, 8, 29-39.

Kimchi-Sarfaty C, Oh JM, Kim IW, et al (2007b). A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science, 315, 525-8.

Kono T, Ogawa H, Tomonaga M, et al (2001). Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors. J Am Soc Nephrol, 13, 1847-54.

Kurzawski M, Drozdzik M, Suchy J, et al (2005). Polymorphism of multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics, 12, 437-50.

Kurzawski M, Leake BF, Choo EF, et al (2001). Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther, 297, 1137-43.

Kurzawski M, Leake BF, Choo EF, et al (2001). Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther, 297, 1137-43.

Kurzawski M, Leake BF, Choo EF, et al (2001). Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther, 297, 1137-43.

Kurzawski M, Leake BF, Choo EF, et al (2001). Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther, 297, 1137-43.

Kurzawski M, Leake BF, Choo EF, et al (2001). Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther, 297, 1137-43.

Kurzawski M, Leake BF, Choo EF, et al (2001). Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther, 297, 1137-43.

Kurzawski M, Leake BF, Choo EF, et al (2001). Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther, 297, 1137-43.

Kurzawski M, Leake BF, Choo EF, et al (2001). Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther, 297, 1137-43.

Kurzawski M, Leake BF, Choo EF, et al (2001). Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther, 297, 1137-43.

Kurzawski M, Leake BF, Choo EF, et al (2001). Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther, 297, 1137-43.
Yue AM, Xie ZB, Zhao HF, et al (2013). Associations of ABCB1 and XPC genetic polymorphisms with susceptibility to colorectal cancer and therapeutic prognosis in a Chinese population. *Asian Pac J Cancer Prev, 14*, 3085-91.

Zebrowska M, Salagacka A, Jelen A, et al (2014). Is the ABCB1 gene associated with the increased risk of gastric cancer development? - preliminary research. *Pathol Res Pract, 210*, 872-8.